Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.
about
Bone Metastasis from Renal Cell CarcinomaMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesFinal results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near futureBone metastases from renal cell carcinoma: patient survival after surgical treatmentType III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathwayC-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy.Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma.Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.Renal cell carcinoma and the use of sorafenib.Microarray profile of human kidney from diabetes, renal cell carcinoma and renal cell carcinoma with diabetes.Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable.Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinibImpact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.Tivozanib in the treatment of renal cell carcinoma.Tissue-based research in kidney cancer: current challenges and future directions.Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease.Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.Review of guidelines on the treatment of metastatic renal cell carcinoma.Suppression of renal cell carcinoma growth and metastasis with sustained antiangiogenic gene therapyManagement of metastatic renal cell carcinoma: current trends.A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma.Renal cell carcinoma: focus on safety and efficacy of temsirolimus.Current treatment considerations in metastatic renal cell carcinoma.Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.New agents in renal cell carcinoma.Update in systemic therapy of urologic malignancies.Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosisOptimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.
P2860
Q26747493-A533BF2F-9595-4665-B757-AEF000F8F214Q26852437-5AF970DA-625B-40DA-A0AD-7375F1789524Q33423740-48634FC5-B145-4D16-89BC-699FB76A93FBQ33435816-D12115AB-38B2-44F3-90E4-B5FD3F5DEA6AQ33599713-9A863309-4D8A-4B2A-BD25-C84344412BAFQ33624261-54FFD646-EE16-457F-A84E-8988DEB2F9EAQ33749558-93E10B6C-9F81-483E-81B0-B53FB234D56AQ34363007-3FF3F817-DE92-483A-95AC-03D5A61EA8DCQ34602155-646D34D3-969F-4743-AD9A-4F85B201BC45Q34713136-B74EE94C-9113-4432-AFE3-D52A5E203483Q35166782-8763DB1E-0A13-4B88-9FA9-26C0186A8ECEQ35184503-58922839-0A42-4F29-BC9B-66EA789480AEQ35909843-B414C492-54FE-4414-BA1F-B1F1EAD2DAB0Q36169696-85F59DE5-6B6B-4DBF-B70F-1ED70E6BCD6BQ36385639-3581D411-4707-4083-B52D-BDAFFCD8CF02Q36485683-69385D6D-A4B1-45F7-8A23-9E4D2461E543Q36611650-41081205-90A2-4D6B-A8DD-EA41133A22B0Q36663566-41550C89-E13E-4255-82B9-597E8766D881Q36807321-28312A5C-8F27-4FA1-B04A-23E4B978CE68Q36810618-BC60678C-DC63-460B-BB60-F1E272C61A03Q36892799-184292DE-A591-46F2-8426-E1A439220818Q36933605-CF14ED09-4299-49B5-B2B7-F2E5E0BCC317Q36982059-771CEB43-2361-4E6E-ACBE-3D392576AF6EQ37003374-52B8E2DA-A3FD-4057-B9BE-61C7CEB5616CQ37111269-D232DA48-7AC6-4319-A391-83B57E5822D8Q37145171-3EE713E6-0B5E-4C30-9980-448CD4F95C4AQ37165231-CEDE620D-0FB2-4EC3-9A65-FA40EB520D3FQ37205893-85D99D26-4781-4DEA-9B99-4E4E546E78C1Q37322679-FCA82108-B873-4783-9C84-FD6E60572F08Q37355884-5A304431-C56C-4E80-871F-F2C047ACE3EEQ37602881-64D235E8-7967-4456-93F6-531C43A16915Q37672155-8AFCDBF2-703D-429E-8DD3-E4BA343827B4Q37828399-D36486D2-2F2E-4506-BE1E-AEA80072750AQ37992827-15A5EFCF-ADB9-4E14-82F8-B4837A213E2FQ38161531-416A9D0F-157F-465C-9A1B-3C69F3F918BCQ38163483-FBD17597-3265-439B-8C9A-EAD106C38904Q38176143-5443E00D-A60D-409B-AAF1-6E33C65588CEQ38409478-C9D8965F-1C4F-45A9-8B76-7A96A80E9D50Q38624864-FF147BD4-A4CB-4593-BFA2-5BAC7F2DB48FQ38762066-71BE7E3D-6443-437B-AD0A-1666666D6D82
P2860
Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prognostic factors for surviva ...... ring cancer center experience.
@ast
Prognostic factors for surviva ...... ring cancer center experience.
@en
type
label
Prognostic factors for surviva ...... ring cancer center experience.
@ast
Prognostic factors for surviva ...... ring cancer center experience.
@en
prefLabel
Prognostic factors for surviva ...... ring cancer center experience.
@ast
Prognostic factors for surviva ...... ring cancer center experience.
@en
P1476
Prognostic factors for surviva ...... ering cancer center experience
@en
P2093
Jennifer Bacik
Madhu Mazumdar
P304
P356
10.1158/1078-0432.CCR-040031
P407
P433
P577
2004-09-01T00:00:00Z